Meta analysis of the influence of diabetes mellitus on lower urinary tract symptoms of patients with benign prostatic hyperplasia

doi:10.3877/cma.j.issn.2095-9605.2017.02.009

Abstract

Abstract:

Objective

To investigate the influence of diabetes mellitus on lower urinary tract symptoms of patients with benign prostatic hyperplasia (BPH).

Methods

The search terms included "diabetes mellitus" "benign prostatic hyperplasia" "lower urinary tract symptoms" in both Chinese and English, and "prostate" "benign prostatic enlargement" in English. PubMed, Cochrane Library, Embase, CNKI, VIP and Wanfang were searched, and the related magazines were also hand-searched. These studies were selected and related data were extracted by two authors independently according to the inclusion and exclusion criteria, and a third author would make a decision when the former two authors couldn't reach an agreement. The extracted data included: (1) general information: first author’s name, publication date, literature resource, design type, sample size; (2) research features: age of the subjects, baseline comparability between the groups; (3) research indexes: total prostate volume (TPV), international prostate symptom score (IPSS), maximum flow rate (Qmax). The STROBE was used to evaluate the quality of included studies, and the State 12.0 software was used for meta-analysis of TPV, IPSS and Qmax.

Results

Six case-control studies and two nested case-control studies were included, and the STROBE scores indicated that all the studies were medium-quality studies. The meta-analysis showed that: (1) the TPV of the BPH patients with diabetes mellitus was significantly higher than that of the BPH patients without diabetes mellitus (P<0.05). (2) Regarding the yellow race, the IPSS of the BPH patients with diabetes mellitus was significantly higher than that of the BPH patients without diabetes mellitus (P<0.05); but regarding the white race, the IPSS of the BPH patients with diabetes mellitus had no statistical difference with that of the BPH patients without diabetes mellitus (P>0.05). (3) Regarding the yellow race, the Qmax of the BPH patients with diabetes mellitus had no statistical difference with that of the BPH patients without diabetes mellitus (P>0.05); but regarding the white race, the Qmax of the BPH patients with diabetes mellitus was significantly lower than that of the BPH patients without diabetes mellitus (P<0.05).

Conclusion

The lower urinary tract symptoms of the BPH patients with diabetes mellitus are more serious than the BPH patients without diabetes mellitus, however more high-quality homogeneity studies are needed to verify it because of the limitations of this research.

Key words: Diabetes mellitus, Benign prostatic hyperplasia, Lower urinary tract symptoms, Meta analysis

Huafu Li, Qun Xie, Xiao Ye, Guangfu Qiu, Qiwei Nie. Meta analysis of the influence of diabetes mellitus on lower urinary tract symptoms of patients with benign prostatic hyperplasia[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2017, 03(02): 97-104.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2017.02.009

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2017/V03/I02/97

Figures/Tables 16

References 26

[1]	Homma Y, Gotoh M, Yokoyama O, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia[J]. Int J Urol, 2011, 18(11):741-756.
[2]	International Diabetes Federation. IDF diabetes atlas sixth edition poster update 2014[EB/OL]. [2014-11-10]． URL
[3]	Bang WJ, Lee JY, Koo KC, et al. Is type 2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?[J]. Urology, 2014, 84(3):670-674.
[4]	Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia[J]. Curr Urol Rep, 2001, 2(4):297-301.
[5]	Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction[J]. Eur Urol, 2015, 67(6):1099-1109.
[6]	Listed N. Standards of medical care in diabetes--2017: summary of revisions[J]. Diabetes Care, 2017, 40(Suppl 1):S4-S5.
[7]	von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting of observational studies[J]. Internist(Berl), 2008, 49(6):688-693.
[8]	Murphy GK, McAlister FA, Weir DL, et al. Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis[J]. BMC Public Health, 2014(14):544.
[9]	Berger AP, Deibl M, Halpern EJ, et al. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia[J]. Diabetologia, 2005, 48(4):784-789.
[10]	Sarma AV, Burke JP, Jacobson DJ, et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men[J]. Diabetes Care, 2008, 31(3):476-482.
[11]	Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia[J]. J Urol, 2000, 163(6):1725-1729.
[12]	帕力达.阿不力孜，玛依拉.阿不都克力木，周晓辉, 等. 糖尿病与良性前列腺增生的相关性研究[J]. 心血管康复医学杂志, 2011, 20(4):303-307.
[13]	Qu X, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients[J]. International Urology & Nephrology, 2014, 46(3):499-504.
[14]	谢南姿，王海峰，罗帮镇, 等. 2型糖尿病与高龄老人良性前列腺增生症的关系研究[J]. 同济大学学报, 2013, 34(3):90-93.
[15]	Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older[J]. World J Urol, 2011, 29(2):171-178.
[16]	Rohrmann S, Smit E, Giovannucci E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III)[J]. Int J Obes, 2005, 29(3):310-316.
[17]	Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia[J]. J Urol, 2002, 168(3):1259-1264.
[18]	Beshay E, Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model[J]. Urology, 2004, 64(5):1062-1067.
[19]	Wang CC, Nagatomi J, Toosi KK, et al. Diabetes-induced alternations in the biomechanical properties of the urinary bladder wall in rats[J]. Urology, 2009, 73(4):911-915.
[20]	Yamaguchi C, Sakakibara RT, Yamamoto T, et al. Overactive bladder in diabetes: a peripheral or central mechanism?[J]. Neurourology & Urodynamics, 2007, 26(6):807-813.
[21]	Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia[J]. Prostate, 2010, 70(1):79-89.
[22]	Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate[J]. Horm Metab Res, 1994, 26(02):81-84.
[23]	Rohrmann S, Platz EA, Giovannucci E. Lifestyle and benign prostatic hyperplasia in older men: what do we know?[J]. Journal of Mens Health & Gender, 2005, 2(2):230-235.
[24]	Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?[J]. Eur Urol, 2007, 51(5):1202-1216.
[25]	Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome[J]. J Clin Invest, 2004, 114(12):1752-1761.
[26]	Ohgaki K, Hikima N, Horiuchi K, et al. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and international prostate symptom Score[J]. Urology, 2011, 77(6):1432-1438.

纳入研究	发表年份（年）	地区	样本量（例）	平均年龄（岁）	STROBE评分（分）	病例组（例）	对照组（例）	研究指标	研究类型
Bang等^[3]	2014	韩国	278	65±9	27	139	139	TPV、IPSS、Qmax	病例对照研究
Boon等^[4]	2001	荷兰	597	66±8	24	32	565	TPV、IPSS、Qmax	病例对照研究
Berger等^[9]	2005	澳大利亚	52	62±4	24	28	24	TPV、IPSS、Qmax	潮式病例对照研究
Sarma等^[10]	2008	美国	2484	56±11	25	170	2314	TPV、Qmax	潮式病例对照研究
Michel等^[11]	2000	德国	7522	68±2	24	1004	6518	IPSS、Qmax	病例对照研究
Abulizi等^[12]	2011	中国	190	71±9	23	90	100	TPV、IPSS、Qmax	病例对照研究
Qu等^[13]	2014	中国	117	78±6	25	64	53	TPV、IPSS	病例对照研究
Xie等^[14]	2013	中国	167	83±5	23	103	64	TPV、IPSS	病例对照研究

纳入研究	发表年份（年）	地区	样本量（例）	平均年龄（岁）	STROBE评分（分）	病例组（例）	对照组（例）	研究指标	研究类型
Bang等^[3]	2014	韩国	278	65±9	27	139	139	TPV、IPSS、Qmax	病例对照研究
Boon等^[4]	2001	荷兰	597	66±8	24	32	565	TPV、IPSS、Qmax	病例对照研究
Berger等^[9]	2005	澳大利亚	52	62±4	24	28	24	TPV、IPSS、Qmax	潮式病例对照研究
Sarma等^[10]	2008	美国	2484	56±11	25	170	2314	TPV、Qmax	潮式病例对照研究
Michel等^[11]	2000	德国	7522	68±2	24	1004	6518	IPSS、Qmax	病例对照研究
Abulizi等^[12]	2011	中国	190	71±9	23	90	100	TPV、IPSS、Qmax	病例对照研究
Qu等^[13]	2014	中国	117	78±6	25	64	53	TPV、IPSS	病例对照研究
Xie等^[14]	2013	中国	167	83±5	23	103	64	TPV、IPSS	病例对照研究

Please choose a citation manager

Content to export